Company Overview - The company specializes in the development of new drugs, including HC-1119, HP518, HP568, HP501, HP515, HP537, and HP560 [8] - The first class new drug, HC-1119, is expected to be approved for sale in May 2025, leading to a modest increase in sales revenue from material and intermediate sales [8] Financial Performance - The company anticipates total revenue for 2025 to be between 19 million and 22 million yuan, influenced by the inclusion of HC-1119 in the National Medical Insurance Drug List, which will result in a significant price reduction [8] - Research and development expenses for 2025 are projected to be between 105 million and 125 million yuan, a decrease of 4.903 million to 6.903 million yuan compared to the previous year [8] - The company expects to report a net loss for 2025, although the loss will be reduced compared to the previous year when excluding non-recurring gains and losses [9] Historical Revenue and Profit Trends - Historical total revenue and net profit data indicate fluctuations, with total revenue expected to show a growth rate of -1,000% to 6,000% from 2020 to 2025 [10] - The company has experienced varying growth rates in total revenue and net profit over the years, with specific projections for 2025 indicating a continued trend of net losses [10] Valuation Metrics - The company’s valuation metrics include price-to-earnings (P/E) ratio, price-to-book (P/B) ratio, and price-to-sales (P/S) ratio, with P/E being negative during loss periods, making P/B and P/S more relevant for valuation [13]

中证智能财讯大唐发电（601991）1月30日晚间披露2025年度业绩预告，预计2025年归母净利润68亿元至78亿元，同比增长51%-73%；扣非净利润预计72亿 元至82亿元，同比增长60%-82%。以1月30日收盘价计算，大唐发电目前市盈率（TTM）约为8.97倍-10.29倍，市净率（LF）约2.05倍，市销率（TTM）约 0.57倍。 公司 -○- 行业均值 制图数据来自恒生聚源数据库 以本次披露业绩预告均值计算，公司近年市盈率（TTM）图如下所示： 近年来市盈率变化情况（倍） 500 450.62 越 00 300 200 156.36 100 26,96 21o76 19654 निर्म 0 1-20 -100 2021-12-37 2021-06-30 ' 2022-12-37 : 2022-06-30 2020-12-37 13-06-30 4-06-30 023-12-37 2n- -○- 公司 -○- 行业均值 )- 公司 -○- 行业均值 制图数据来自恒生聚源数据库 100 993 ହ 90 80 70 60 50 40 3dros 30 24d2 20 15.88 10 0 202 ...

Core Viewpoint - The company Yi Da Co., Ltd. (300721) has announced a forecast for a net loss of 100 million to 120 million yuan for the year 2025, a significant decline from a profit of 9.53 million yuan in the same period last year [4]. Financial Performance - The expected net profit loss for 2025 is between 100 million to 120 million yuan, compared to a profit of 9.53 million yuan in the previous year [4]. - The expected non-recurring net profit loss is also between 100 million to 120 million yuan, down from a profit of 1.14 million yuan in the same period last year [4]. - The company's price-to-book ratio (LF) is approximately 2.56 times, and the price-to-sales ratio (TTM) is about 1.87 times based on the latest closing price [4]. Business Operations - The company primarily engages in the research, production, and sales of chemical products such as alcohol ethers, alcohol ether esters, hydrogen peroxide, and propylene oxide [13]. - Sales volume for alcohol ethers and alcohol ether esters has continued to grow, leading to increased capacity utilization and a decrease in unit product costs due to lower raw material prices [13]. - However, due to market competition, the sales prices of alcohol ethers and alcohol ether esters have decreased significantly, resulting in a notable decline in gross profit margins [13]. - In the fourth quarter, particularly in November 2025, the market price for propylene oxide showed signs of recovery, and the subsidiary Tai Xing Yi Da's production capacity utilization increased significantly [13]. - The company has implemented energy-saving upgrades and process optimizations, leading to a noticeable reduction in costs for propylene oxide [13]. Future Outlook - The production volume of hydrogen peroxide has slightly decreased, and its sales prices have also dropped, leading to a decline in gross profit margins [14]. - The company plans to accelerate the implementation of propylene (ethylene) derivatives projects while enhancing product quality and cost control to improve profitability and operational performance [14].

Core Viewpoint - Asia-Pacific Pharmaceutical (002370) expects to achieve operating revenue of 350 million to 370 million yuan and a net profit attributable to shareholders of 100 million to 120 million yuan for the year 2025, representing a year-on-year growth of 192.06% to 250.47% [4] Financial Performance - The company anticipates a non-recurring net profit loss of 42 million to 60 million yuan, compared to a loss of 28.13 million yuan in the same period last year [4] - Basic earnings per share are projected to be between 0.13 yuan and 0.16 yuan [4] Valuation Metrics - As of January 30, the company's price-to-earnings (P/E) ratio (TTM) is approximately 44.18 to 53.02 times, the price-to-book (P/B) ratio (LF) is about 4.73 times, and the price-to-sales (P/S) ratio (TTM) is around 14.73 times [4] Business Operations - The main business of the company involves pharmaceutical manufacturing, including the research, production, and sales of chemical preparations [11] - The increase in profit for 2025 is attributed to the sale of the wholly-owned subsidiary Shaoxing Xingya Pharmaceutical Co., Ltd., which is expected to add approximately 149 million yuan to the company's total profit for the year (non-recurring gains) [11]

Core Viewpoint - The company Mengbaihe (603313) has announced a positive earnings forecast for 2025, projecting a net profit attributable to shareholders between 90 million to 130 million yuan, a significant recovery from a loss of 151 million yuan in the previous year [4] Financial Performance - The expected net profit for 2025 represents a turnaround from the previous year's loss, with a projected non-recurring net profit of 50 million to 70 million yuan, compared to a loss of 280 million yuan last year [4] - Historical financial data shows a trend of recovery, with the company moving from significant losses in prior years to expected profitability in 2025 [5] Valuation Metrics - As of January 30, the company's price-to-earnings (P/E) ratio is estimated to be between 43.8 and 63.27 times, with a price-to-book (P/B) ratio of approximately 1.54 times and a price-to-sales (P/S) ratio of about 0.63 times [4] - The P/E and P/S ratios are calculated using trailing twelve months (TTM) data, while the P/B ratio is based on the latest financial report [9] Business Operations - Mengbaihe focuses on the research, development, production, and sales of home products aimed at enhancing deep sleep, including memory foam mattresses, pillows, sofas, electric beds, and other home goods [4] - The company attributes its improved performance to a reduction in asset impairment losses and strengthened market expansion efforts, particularly in domestic and international markets, along with enhanced brand development and online business growth [4]

中证智能财讯苏宁环球（000718）1月30日晚间披露2025年度业绩预告，预计2025年归母净利润2000万元至3000万元，同比下降81.84%-87.89%；扣非净利润 预计2500万元-3750万元，同比下降74.36%-82.9%；基本每股收益0.0066元/股-0.0099元/股。以1月30日收盘价计算，苏宁环球目前市盈率（TTM）约为236.7 倍-355.05倍，市净率（LF）约0.77倍，市销率（TTM）约4.6倍。 以本次披露业绩预告均值计算，公司近年市盈率（TTM）图如下所示： 近年来市盈率变化情况（倍） 300 (200 100 34x89 31o57 25o75 23-99 23x53 22.82 1563 8 वन 0 -100 2021-12-37 2022-06-30 2020-12-37 2021-06-30 ' 2022-12-37 3-06-30 23-12-37 2n- -○- 公司 -○- 行业均值 100 ହ 90 80 70 7000 64.84 60 55.35 50 50-67 47x89 4968 40 30 23.02 20 10 6.d7 0 2027- ...

Group 1 - The company focuses on smart city, smart energy, smart healthcare, and identity verification sectors, providing services to various industries including government, healthcare, emergency services, public security, and finance [8] - The company adheres to a "one body, two wings" development strategy, continuously deepening its industrial layout and actively expanding its core business areas [8] - The company has a sufficient backlog of orders at the end of the reporting period, driven by enhanced R&D innovation and improved project management systems [8] Group 2 - Non-recurring gains and losses are expected to impact the company's net profit by approximately 7.5 million [9] - Historical net profit and non-recurring profit growth rates are presented, indicating fluctuations in profitability over the years [11] - The company’s net profit and non-recurring net profit have shown significant variations, with a notable decline in certain years [12]

Group 1 - The company Guancheng New Materials (600067) expects a net profit attributable to shareholders of 60 million to 90 million yuan for the year 2025, a significant recovery from a loss of 667 million yuan in the previous year [4] - The expected net profit excluding non-recurring items is projected to be between 57 million and 85 million yuan, compared to a loss of 687 million yuan in the same period last year [4] - As of January 30, the company's price-to-earnings ratio (TTM) is approximately 65.72 to 98.58 times, with a price-to-book ratio (LF) of about 1.05 times and a price-to-sales ratio (TTM) of around 0.56 times [4] Group 2 - The company's main business includes the production and sales of electromagnetic wires, real estate development, and the production of additives for lithium battery electrolytes [14] - During the reporting period, the sales volume of the electromagnetic wire business increased compared to the same period last year, and the company expects its annual operating revenue to exceed that of the previous year [14] - The significant losses in the previous year were primarily due to large impairment provisions made for certain real estate projects based on market conditions and sales performance [14]

Core Viewpoint - Guangdong Mingzhu (600382) expects a significant increase in net profit for 2025, projecting a growth of 2908.49% to 3577.04% year-on-year, driven by operational improvements and increased sales in iron ore and construction materials [4]. Financial Performance - The company forecasts a net profit attributable to shareholders of 166 million to 203 million yuan for 2025, and a non-recurring net profit of 175 million to 213 million yuan, reflecting a year-on-year increase of 422.59% to 538.72% [4]. - As of January 30, the company's price-to-earnings (P/E) ratio is approximately 32.64 to 39.9 times, with a price-to-book (P/B) ratio of about 2.44 times and a price-to-sales (P/S) ratio of around 7.92 times [4]. Operational Factors - The increase in profit is attributed to the full subsidiary Guangdong Mingzhu Group Mining Co., which has seen a 160.83% increase in iron concentrate sales due to new mining operations and technological upgrades in production lines [14]. - The company expects a net profit from the mining segment to be between 349.45 million to 427.11 million yuan, representing a year-on-year increase of 208.00% to 276.45% [14]. Non-Operating Factors - The company anticipates a decrease in expenses related to investor claims for securities fraud, compared to the previous year [16]. - Gains from the fair value changes of stock investments are expected to increase by 1.09 million yuan year-on-year [17]. Impairment and Valuation Adjustments - The company plans to increase impairment provisions for real estate projects due to ongoing legal issues, with an expected credit impairment of approximately 93.64 million yuan, a year-on-year increase of about 485.86% [18].

Core Viewpoint - Zhengfan Technology (688596) expects a decline in revenue and net profit for the year 2025, indicating challenges in the market and operational environment [4]. Financial Performance Summary - The projected revenue for 2025 is between 4.8 billion to 5.1 billion yuan, representing a year-on-year decrease of 7% to 12% [4]. - The expected net profit attributable to shareholders is between 110 million to 150 million yuan, reflecting a significant decline of 72% to 79% year-on-year [4]. - The forecasted net profit excluding non-recurring items is estimated to be between 65 million to 95 million yuan, indicating a decrease of 81% to 87% year-on-year [4]. Valuation Metrics - As of January 30, the price-to-earnings ratio (TTM) is approximately between 65.14 and 88.83 times, while the price-to-book ratio (LF) is about 2.71 times, and the price-to-sales ratio (TTM) is around 1.97 times [4]. Factors Influencing Performance - The decline in performance is attributed to several factors: 1. A slowdown in capital expenditure from downstream industries, increased market competition, and delays in project deliveries, leading to reduced revenue and gross profit [13]. 2. Increased depreciation due to the concentrated use of newly built production capacity [13]. 3. Rising financial costs from investments, bank loans, and convertible bond issuances [13].